- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.02. | Inhibikase enhances leadership with new appointments | 1 | Investing.com | ||
| 18.02. | Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth | 108 | GlobeNewswire (Europe) | -- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON... ► Artikel lesen | |
| 18.02. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.02. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 30.01. | Inhibikase hits pause on Parkinson's program over efficacy as it prioritizes lung drug | 1 | FierceBiotech | ||
| 29.01. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.01. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.12.24 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.11.24 | Inhibikase Therapeutics files for secondary offering of common stock | 3 | Seeking Alpha | ||
| 14.11.24 | Inhibikase Therapeutics GAAP EPS of -$0.65 misses by $0.17 | 2 | Seeking Alpha | ||
| 14.11.24 | Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity | 173 | GlobeNewswire (Europe) | -- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial... ► Artikel lesen | |
| 14.11.24 | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10.24 | Hedge Fund and Insider Trading News: D.E. Shaw, David Einhorn, Bill Ackman, Crispin Odey, Ken Griffin, Elliott Investment Management, Bridgewater Associates, Inhibikase Therapeutics Inc (IKT), Micron Technology Inc (MU), and More | 45 | Insider Monkey | ||
| 22.10.24 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.10.24 | Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension | 175 | GlobeNewswire (Europe) | -- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and... ► Artikel lesen | |
| 14.10.24 | H.C. Wainwright senkt Kursziel für Inhibikase Therapeutics; behält Kaufempfehlung bei | 3 | Investing.com Deutsch | ||
| 14.10.24 | Inhibikase Therapeutics stock target cut by H.C. Wainwright; retains Buy rating | 1 | Investing.com | ||
| 09.10.24 | Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today | 1 | Benzinga.com | ||
| 09.10.24 | Inhibikase Therapeutics stock rises after pricing $110M private offering | 2 | Seeking Alpha | ||
| 09.10.24 | Inhibikase Therapeutics announces $110 million financing | 2 | Investing.com |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 196,30 | +0,22 % | AKTIONÄR-Depotwert Gubra: Hammer-Deal mit AbbVie - die Details! | Paukenschlag zum Wochenstart: AKTIONÄR-Depotwert Gubra hat eine Lizenzvereinbarung mit dem Pharma-Riesen AbbVie unter Dach und Fach gebracht. Die Amerikaner sichern sich die Rechte an einem Amylin-Projekt... ► Artikel lesen | |
| TEVA | 14,800 | 0,00 % | Teva Pharmaceutical Industries Ltd: Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March | TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 5,926 | +3,31 % | EyePoint Pharmaceuticals Q4 2024 Earnings Preview | ||
| BAUSCH HEALTH | 6,642 | +0,45 % | Bausch Health Companies Inc.: Bausch Health Announces Fourth Quarter and Full-Year 2024 Results | Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidanceFourth Quarter Consolidated Revenues... ► Artikel lesen | |
| ORGANIGRAM | 1,064 | +2,50 % | ORGANIGRAM HOLDINGS INC. - 6-K, Report of foreign issuer | ||
| QUANTUM BIOPHARMA | 4,040 | +2,02 % | Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302 | Safety Review Committee Found No Safety Concerns Following Milestone Trial TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma"... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 6,210 | +1,72 % | Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem | -- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum --
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 132,35 | +1,11 % | Jazz Pharmaceuticals (NASDAQ:JAZZ) Releases Earnings Results, Misses Estimates By $0.13 EPS | ||
| SELLAS LIFE SCIENCES | 1,184 | +5,90 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL | - Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,904 | -6,03 % | XORTX initiiert Gichtprogramm und NDA-Gespräche mit der FDA | - Typ-C-Meeting ist Voraussetzung für
die Einleitung eines verkürzten NDA-Zulassungsverfahrens für XRx-026 zur Gichtbehandlung
CALGARY, AB - 24. Februar 2025 / IRW-Press... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 31,430 | -0,60 % | Prediction: BridgeBio Pharma Will Beat the Market. Here's Why | ||
| MADRIGAL PHARMACEUTICALS | 304,20 | +0,33 % | Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.8% Following Insider Selling | ||
| VERONA PHARMA PLC ADR | 64,00 | 0,00 % | AKTIONÄR-Tipp Verona Pharma: Bärenstarker Launch - da geht noch mehr | Das neuartige Medikament Ohtuvayre zur Behandlung der chronisch obstruktiven Lungenerkrankung (COPD) von Verona Pharma wird weiter aus den Regalen gerissen. Mit den Zahlen zum vierten Quartal respektive... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,089 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 10-K, Annual Report | ||
| OPUS GENETICS | 0,921 | -3,76 % | Opus Genetics, Inc. - 8-K, Current Report |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 2,205 Euro und damit -2,86 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.
